Results 51 to 60 of about 287,041 (297)
Molecular Oncology, EarlyView.Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen +12 more
wiley +1 more source
Monitoring Value of Serum HER2 as a Predictive Biomarker in Patients with Metastatic Breast Cancer
Cancer Management and Research, 2020 Pengyu Zhang,1,* Jun Xiao,2,* Yingxin Ruan,3,* Zhenzhen Zhang,1 Xuejun Zhang2 1Department of Blood Transfusion, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and
Zhang P +4 more
doaj
Molecular Oncology, EarlyView.This study investigates gene expression differences between two major pediatric acute lymphoblastic leukemia (ALL) subtypes, B‐cell precursor ALL, and T‐cell ALL, using a data‐driven approach consisting of biostatistics and machine learning methods. Following analysis of a discovery dataset, we find a set of 14 expression markers differentiating the ...
Mona Nourbakhsh +8 more
wiley +1 more source
Overcoming Challenges in Cancer Care: A Focus on Emerging Technologies
BiomedicinesCancer research is rapidly evolving, propelled by advancements in molecular biology, genomics, and immunology [...]
Aya Hasan Alshammari +2 more
doaj +1 more source
Molecular Oncology, EarlyView.The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song +11 more
wiley +1 more source
Molecular Oncology, EarlyView.C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald +18 more
wiley +1 more source
Synthetic immunology: T-cell engineering and adoptive immunotherapy
Synthetic and Systems Biotechnology, 2018 During the past decades, the rapidly-evolving cancer is hard to be thoroughly eliminated even though the radiotherapy and chemotherapy do exhibit efficacy in some degree. However, a breakthrough appeared when the adoptive cancer therapy [1] was developed,
Wen Si, Cheng Li, Ping Wei
doaj
Nature Communications, 2018 The costimulatory T-cell receptor 4-1BB is an immuno-oncology target. Here the authors present the ligand bound 4-1BB receptor crystal structure in addition to the structures of 4-1BB bound with two therapeutic antibodies and verify the antibody binding ...
S. Michael Chin +15 more
doaj +1 more source
Molecular Oncology, EarlyView.Analysis of treatment‐naïve high‐grade serous ovarian carcinoma (HGSOC) and control tissues for ERVs, LINE‐1 (L1), inflammation, and immune checkpoints identified five clusters with diverse patient recurrence‐free survivals. An inflammation score was calculated and correlated with retroelement expression, where one novel cluster (Triple‐I) with high ...
Laura Glossner +6 more
wiley +1 more source
The sweet side of immune evasion: role of glycans in the mechanisms of cancer progression
Frontiers in Oncology, 2016 Glycans are part of the essential components of a cell. These compounds play a fundamental role in several physiopathological processes including cell differentiation, adhesion, motility, signal transduction, host-pathogen interactions, tumor cell ...
Ana Flávia Fernandes Ribas Nardy +3 more
doaj +1 more source